A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

Pharmaceutical industry Archive

Delivering Value in Rare Diseases

Posted by | 10:56am on Monday, February 29, 2016 | No Comments
Hidden Value of Orphan Drugs

Debates about high drug prices have dominated many of the headlines this year.  Raise the price of a drug 5,000% and you will definitely get everyone’s attention, including the feds.

It’s unfortunate to see the occasional bad actors getting so much press, given the inspiring progress made by all of the companies and communities diligently working to find treatments, especially when you consider those with rare diseases. Thirty million people in America are impacted by rare disease and 95% of those disorders lack treatment. Don’t let the headlines mislead you. The real news is that continued investment in rare disease innovation helps everyone.

We hope you’ll share our 4th annual Rare Disease Infographic that focuses on these innovations:

  • Record levels of investment leading to record levels of FDA approvals
  • NIH and advocacy groups funding early research
  • Research on orphan drugs that opens the door to new treatments for common ailments
  • New distribution models that reduce costs through direct patient engagement and personal support
  • Foundations and compliance experts working to accelerate the approval process by improving research and public policy

As the number of orphan drug designations and approvals rises, there will likely be more questions raised about the cost.  The customary response is that research is more challenging in rare diseases or that knowledge gained from rare informs the common, both of which are true.

But as the emphasis on reducing costs in healthcare grows, perhaps the best response orphan drug makers can make is to demonstrate value. That isn’t just about costs.  It’s about patient experience, quality of care and maximizing outcomes.

Understanding how best to accomplish this requires a paradigm shift. Delivering value in orphan drugs requires a fundamentally different strategy, because rare patients and families face a whole host of financial, medical and lifestyle challenges that require a sophisticated system of support.

In the end, it will be the patients themselves that teach us what good looks like in rare disease. Whether it’s a matter of determining meaningful endpoints for clinical trials or designing a program to increase adherence, the best way to deliver value is to listen to them.

Why Transparency Matters More Than Ever

Relationships are important in rare—and so are reputations. Rare disease communities are often small and closely knit. Patients and caregivers…

What We Want From (Big) Pharma

We are honored to share this guest post from Melissa Hogan, founder of Saving Case. Melissa started the organization after…

Lessons from Pharma Leaders

On March 7, 2012 I attended a Healthcare Businesswomen’s Association (HBA) event, “Strengths-Based Leadership.” The panel featured Freda Lewis-Hall, MD,…

The First FDA Rare Disease Patient Advocacy Day

We are pleased to feature a guest blog post from Catherine Sohn. She has more than 20 years of pharmaceutical…

Screen shot 2012-03-07 at 12.03.12 PM

Patients at the Center at The Economist Pharma Summit

On February 9, I had the opportunity to speak at The Economist Pharma Summit 2012 in London. I was invited…

How Patients & Pharma Both Benefit from Digital Resources

The latest Manhattan Research ePharma Consumer® study confirmed that pharma-supported interactive materials benefit both patients and pharma. Reliance on pharma-sponsored…

Pharma Marketing Tweetchat Celebrates 1st Anniversary

I’m proud to say it’s been a year since the first pharmaceutical marketing and social media tweetchat, #SocPharm. The #SocPharm…

What Do You Think Makes a Successful Pharmaceutical Blog?

The other day I completed a survey evaluating pharmaceutical blogs, which got me thinking about the space. The questionnaire, from…

Consumers Don’t Trust Pharma,
So What Can We Do?

I’ve written about the lack of trust consumers have in pharmaceutical companies before, so the latest Harris research isn’t a surprise….

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com